Maximum quantity allowed is 999
请选择数量
CAS RN: 21829-25-4 | 产品编码: N0528
Nifedipine
×
![]()
×
| 规格 | 单价 | 同一天 | 2-3个工作日 | 数量 |
|---|---|---|---|---|
| 10G |
S$72.00
|
13 | ≥40 |
|
| 25G |
S$132.00
|
33 | 13 |
|
技术规格
| Appearance | Light yellow to Yellow to Orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(UV-vis method) | min. 98.0 % |
| Melting point | 172.0 to 175.0 °C |
| Solubility in Acetone | almost transparency |
| NMR | confirm to structure |
物性（参考值）
| 熔点 | 174 °C |
| 溶解性（可溶于） | 氯仿, 丙酮 |
GHS
| 象形图 |
|
| 信号词 | Warning |
| 危险性说明 | H302 : Harmful if swallowed. |
| 防范说明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
相关法规
| RTECS# | US7975000 |
运输信息
| HS编码* | 2933.39-000 |
应用
Type IV secretion system (T4SS) research
Reference
- Chemical Genetics Reveals Bacterial and Host Cell Functions Critical for Type IV Effector Translocation by Legionella pneumophila
应用
Nifedipine: A Short-Acting Dihydropyridine Calcium Antagonist
Nifedipine is a short-acting dihydropyridine calcium antagonist. It selectively inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle without altering serum calcium concentrations, and induces a relaxation of the muscle. Because of the dilation of resistance vessels, blood pressure falls. Nifedipine is almost completely metabolized by cytochrome P450 3A4 (CYP3A4) in the liver. Nifedipine is a poorly water soluble agent and rapidly metabolized resulting in decreased bioavailability, and then the short-acting can provide increased the risk of stroke et al. Therefore, nifedipine slow-release formulations have been developed. (The product is for research purpose only.)
References
- Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischemic heart disease, hypertension and related cardiovascular disorders
- Comparative pharmacology of calcium antagonists: nifedipine, verapamil [V0118] and diltiazem [D3662] (a review)
- Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine
- In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: Role of CYP3A4 and CYP3A5
- Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris (a review)
- Analysis of nifedipine and its pyridine metabolite dehydronifedipine in blood and plasma: review and improved high-performance liquid chromatographic methodology
应用
Photobase Generator
References
- S. Song, S. Yokoyama, S. Takahara, T. Yamaoka, Polym. Adv. Technol. 1998, 9, 326.
- S. Song, S. Takahara, T. Yamaoka, J. Photopolym. Sci. Technol. 1998, 11, 171.
参考文献
文章/手册
TCIMail
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。